IBI3040 / Innovent Biologics - LARVOL DELTA

Clinical Trials of IBI3040 in Healthy Participants and Overweight or Obese Participants (clinicaltrials.gov) - P1 | N=96 | Not yet recruiting | Sponsor: Innovent Biologics (Suzhou) Co. Ltd.

New P1 trial • Obesity

IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models (ADA 2026) - "IBI3040 demonstrates superior receptor activation, robust weight loss effects, and synergistic potential with semaglutide, supporting its development as a next-generation amylin analog for obesity treatment."

Late-breaking abstract • Preclinical • Metabolic Disorders • Obesity

ADA Reference: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models (Abstract No.: 3077-LB) (PRNewswire) - "IBI3040 is a highly potent agonist of the amylin and calcitonin (CTR) receptors. In a 2-week study in DIO rats, IBI3040 at 2 and 10 nmol/kg Q3D resulted in dose-dependent reductions in body weight of 8.82% and 11.11%, respectively, compared to vehicle-treated rats. In another study, the combination of IBI3040 and semaglutide resulted in a greater weight reduction of −14.7%, whereas monotherapy with IBI3040 or semaglutide produced weight losses of −10.12% and −3.01% in DIO rats, respectively, indicating an additive effect of the combined treatment. Compared to cagrilintide, IBI3040 displays a favorable PK profile, high solubility, and stability without fibril formation at physiological pH (7-8)."

Preclinical • Obesity

Innovent to Present Multiple Clinical and Preclinical Results of Mazdutide and Next-Generation Obesity & Metabolic Pipeline at the 2026 ADA Scientific Sessions (PRNewswire) - "'The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032 (oral daily GLP-1 small molecule), IBI3042 (oral weekly GLP-1 small molecule), IBI3040 (amylin) and IBI3046 (INHBE siRNA) represent key milestones of our next‑generation obesity pipeline with global potential...'"

Clinical data • P3 data • Preclinical • Obesity • Type 2 Diabetes Mellitus